The Technical Analyst
Tarsus Pharmaceuticals, [TARS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Tarsus Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.40% $34.94
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 310.25 mill |
| EPS: | -4.62 |
| P/E: | -7.56 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 37.50 mill |
| Avg Daily Volume: | 0.786 mill |
| RATING 2024-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.56 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.29x |
| Company: PE -7.56 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$6.43 (-81.61%) $-28.51 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 32.89 - 37.15 ( +/- 6.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Mottiwala Aziz | Buy | 12 938 | Common Stock |
| 2024-03-18 | Mottiwala Aziz | Sell | 4 766 | Common Stock |
| 2024-03-15 | Mottiwala Aziz | Sell | 8 148 | Restricted Stock Units |
| 2024-03-15 | Mottiwala Aziz | Sell | 4 790 | Restricted Stock Units |
| 2024-03-15 | Wahl Bryan | Buy | 12 038 | Common Stock |
| INSIDER POWER |
|---|
| 30.97 |
| Last 100 transactions |
| Buy: 1 038 524 | Sell: 656 594 |
Forecast:
16:00 - $35.03
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $35.03
Forecast 2: 16:00 - $35.03
Forecast 3: 16:00 - $35.03
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $34.94 (-3.40% ) |
| Volume | 0.322 mill |
| Avg. Vol. | 0.786 mill |
| % of Avg. Vol | 41.00 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TARS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $31.39 | N/A | Active |
|---|
TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Latest Press Releases
2024-03-05 16:30:00 - Press Release
Tarsus To Participate At Upcoming Investor Conferences
Irvine, calif., march 05, 2024 (globe newswire) -- tarsus pharmaceuticals, inc. (nasdaq: tars), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that tarsus will participate in the following conferences:
2024-03-05 08:30:00 - Press Release
Tarsus Introduces “mite Party” Campaign For Xdemvy® (lotilaner Ophthalmic Solution) 0.25% To Educate Consumers About Demodex Blepharitis
Unique and memorable campaign intended to educate consumers about demodex blepharitis and xdemvy, the first and only fda approved solution for the disease
2024-03-01 00:07:00 - Press Release
Tarsus Announces Pricing Of $100.0 Million Public Offering
Irvine, calif., march 01, 2024 (globe newswire) -- tarsus pharmaceuticals, inc. (nasdaq: tars) (the “company” or “tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the pricing of an underwritten public offering of 2,812,500 shares of its common stock at a public offering price of $32.00 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 312,500 shares of its common stock at a public offering price of $31.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant...
2024-02-29 16:37:00 - Press Release
Tarsus Announces Proposed $100.0 Million Public Offering
Irvine, calif., feb. 29, 2024 (globe newswire) -- tarsus pharmaceuticals, inc. (nasdaq: tars) (the “company” or “tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. all securities in the proposed offering are to be sold by tarsus...
2024-02-27 06:00:00 - Press Release
Tarsus Reports Strong Fourth Quarter And Full-year 2023 Financial Results And Recent Business Achievements
Launched xdemvy ® (lotilaner ophthalmic solution) 0.25%, for the treatment of demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four months since launch
Latest News
2024-04-08 10:56:04 - Zacks Investment Research
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 47.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-04-01 13:00:49 - Zacks Investment Research
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
Tarsus Pharmaceuticals (TARS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-07 20:03:34 - Seeking Alpha
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new indications with the US Food and Drug Administration. TARS has also reported sales of $13.1M from the first full quarter of Xdemvy's launch as a treatment for Demodex blepharitis.
2024-03-06 10:56:10 - Zacks Investment Research
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Tarsus Pharmaceuticals, Inc. (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-03-05 16:30:00 - GlobeNewsWire
Tarsus to Participate at Upcoming Investor Conferences
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will participate in the following conferences:
2024-02-28 13:01:07 - Zacks Investment Research
Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy
Does Tarsus Pharmaceuticals, Inc. (TARS) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-20 17:00:00 - GlobeNewsWire
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
2024-01-30 05:11:03 - Zacks Investment Research
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2023-12-04 12:09:00 - Seeking Alpha
Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway
TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with one due in Q4'23. TARS completed a follow-on offering in August, raising net proceeds of $99.4M. TARS had $246.9M in cash at the end of Q3'23.
2023-11-10 18:59:09 - Seeking Alpha
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CCO Jeff Farrow - CFO, CSO Conference Call Participants Jason Gerberry - Bank of America Eddie Hickman - Guggenheim Securities Oren Livnat - H.C. Wainwright Frank Brisebois - Oppenheimer Operator Good afternoon and welcome to the Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.